SAN FRANCISCO, October 26, 2022 /PRNewswire/ — The global mycoplasma testing market size is expected to reach 2.2 billion dollars by 2030, according to a new report from Grand View Research, Inc. The market is expected to expand at a CAGR of 13.2% from 2022 to 2030. The major factors driving the expansion of the market include increasing demand for mycoplasma testing in biological manufacturing, developing economies, and increasing pharmaceutical contracting. Moreover, the overall growth of the market is driven by the growth in cell line pollution and innovation and research in life sciences.
Key industry insights and findings from the report:
- By product, kits and reagents dominated the market and are projected to exhibit the fastest CAGR throughout the forecast period, owing to their widespread use in mycoplasma testing
- By technology, the polymerase chain reaction segment held a larger share in 2021, which can be attributed to the technology’s ability to deliver fast and accurate findings
- Ease of performing the procedure and rapid detection are some of the main advantages that the PCR method offers
- By application, cell line testing segment held a larger share in 2021. growing risk of cell line contamination
- Mycoplasma contamination can cause changes in cell culture metabolites and lead to the development of toxins. This increases the importance of cell line testing and validation in the pharmaceutical and biopharmaceutical industry
- North America held the largest share in 2021. This is mainly attributed to the presence of important market participants, as well as increased R&D spending and federal assistance
- IN Asia Pacificthe market is expected to grow at the highest rate over the forecast period driven by factors such as increasing prevalence of target diseases with an aging population, increasing awareness and others
Read the 150-page market research report, “Mycoplasma Testing Market Size, Segmentation and Trends Analysis by Product (Instruments, Kits and Reagents), By Technology (PCR, ELISA), By Application (Cell Line Testing, Viral Testing), By End Use, Forecasts of region and segment, 2022 – 2030“, published by Grand View Research.
Mycoplasma Testing Market Growth and Trends
The increasing number of government initiatives to support pharmaceutical and biotechnology companies is also fueling the market growth. The US FDA proposed removing a test for the detection of mycoplasma within live cell cultures in vitro, as only a single test method can help identify it. These changes in biological regulations are expected to improve the specificity and sensitivity in mycoplasma detection tests, leading to the introduction of new technologies in the industry. This is expected to create tremendous opportunities for key players in new product development.
M. pneumoniae positivity rates decreased significantly during the outbreak of the COVID-19 pandemic in late 2019. This was a result of strict COVID-19 pandemic regulations, which successfully stopped the spread of M. pneumoniae. However, M. pneumonia is predicted to expand even more throughout the research period after the relaxation of the COVID-19 limits, which will have a positive impact on the growth of the mycoplasma testing market.
Increased investments in R&D have contributed significantly to the growth of market revenues. As healthcare spending increases, research activities in the life sciences industry are increasing significantly. Adoption of new technologies for drug discovery and development and innovations in cell culture technologies are driving the demand for mycoplasma tests. High risk of cell culture contamination remains the major factor expected to drive the mycoplasma testing market during the forecast period.
Mycoplasma is estimated to contaminate about 15%-35% of all continuous cell cultures worldwide. Of the over 190 known mycoplasma species, only eight species are responsible for more than 95% of cell culture contamination. Poor cultural practices, aerosols, dust, and cross-contamination as a result of faulty or broken laminar flow are some of the factors responsible for increasing the number of cell culture contamination events. Such factors are likely to drive the market demand for mycoplasma testing solutions.
Mycoplasma Testing Market Segmentation
Mycoplasma Testing Market Segmentation
Grand View Research has segmented the global mycoplasma testing market on the basis of product, technology, application, end-use and region:
Mycoplasma Testing Market – Product Forecast (Revenue, USD Million, 2018 – 2030)
- instruments
- Kits and reagents
- PCR analyses
- Nucleic acid detection kits
- STUBBORN STAINS
- Elimination kits
- Standards & Controls
- Others
- service
Mycoplasma Testing Market – Technology Outlook (Revenue, USD Million, 2018 – 2030)
- PCR
- ELISA
- Direct analysis
- Indirect analysis
- Microbial Culture Techniques
- Enzymatic methods
Mycoplasma Testing Market – Application Forecast (Revenue, USD Million, 2018 – 2030)
- Mobile line testing
- Virus testing
- End of production cell testing
- Others
Mycoplasma Testing Market – End-Use Outlook (Revenue, USD Million, 2018 – 2030)
- Academic Research Institutes
- Cell banks
- Contract research organizations
- Pharmaceutical and Biotechnology Companies
- Others
Mycoplasma Testing Market – Regional Outlook (Revenue, USD Million, 2018 – 2030)
- North America
- Europe
- Germany
- uk
- France
- Ital
- Spain
- Russia
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
List of Major Players in Mycoplasma Testing Market
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Lonza Group AG
- Charles River Laboratories International, Inc.
- PromoCell GmbH
- American Type Culture Collection
- Asahi Kasei Medical Co., Ltd.
- Sartorius AG
- InvivoGen
- Eurofins Scientific
Check out more related studies published by Grand View Research:
- Plasma fractionation market – The global plasma fractionation market is expected to reach 58.24 billion dollars to 2030, expanding at a CAGR of 8.3%, according to a new report from Grand View Research, Inc. The major factors driving the market growth are the increasing prevalence of respiratory diseases globally, blood-related diseases and an aging population that is prone to a variety of rare disorders. These are the main drivers of market expansion. Moreover, the growth of the market also complemented the increasing prevalence of rare disorders that require plasma or derivative therapy.
- The stem cell market – The global stem cell market size is expected to reach 31.6 billion dollars by 2030, registering a CAGR of 11.4% from 2022 to 2030, according to a new report from Grand View Research, Inc. Stem cells are cells that can differentiate into a variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years to assess the true potential of stem cells, leading to a variety of applications in the fields of treatment of genetic diseases, neurological disorders, oncology and organ regeneration.
- The Forensic Technology Market – The size of the global forensic technology market is expected to reach 10.64 billion dollars by 2030, according to a new report from Grand View Research, Inc. The market is projected to expand at a CAGR of 10.2% from 2022 to 2030. New innovations in forensic science Research and Development (R&D) have introduced progressive techniques that have increased the efficiency of forensic analysis.
Browse through Grand View Research’s Biotechnology Industry Research Reports.
About Grand View Research
Grand View Research, the US-based market research and consulting company, offers shared as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company consists of over 425 analysts and consultants, adding more than 1,200 market research reports to its extensive database each year. These reports provide in-depth analysis on 46 industries in 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and assess the opportunities ahead.
Contact:
Sherry James
Corporate Sales Specialist, US
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Website: https://www.grandviewresearch.com
Large View Compass | Astra ESG Solutions
Follow us: LinkedIn | I tweet
Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
SOURCE Grand View Research, Inc.
